Clinical Trial Update: Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260) [Phase 2]

View source ↗

Summary

Phase 2 study CA209-260 in advanced melanoma and bladder cancer examined the relationship between tumor mutation burden and predicted neoantigen burden in patie…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Melanoma

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Bladder Cancer, Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2025-07-22